# Planet Labs PBC: financial statements, quarterly

PL · NYSE · CIK 1836833 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/pl.md) · [Financials](/companies/pl/financials.md) · [Filings](/companies/pl/filings.md) · [Insiders](/companies/pl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [55.4](/filings/0001836833-24-000118.md) | [58.9 d](/filings/0001193125-26-119957.md) | [60.4](/filings/0001836833-25-000063.md) | [61.1](/filings/0001836833-25-000104.md) | [61.3](/filings/0001193125-25-314295.md) | [61.6 d](/filings/0001193125-26-119957.md) | [66.3](/filings/0001193125-26-258304.md) | [73.4](/filings/0001193125-26-382016.md) | [81.3](/filings/0001193125-25-314295.md) | [86.8 d](/filings/0001193125-26-119957.md) | [94.2](/filings/0001193125-26-258304.md) | [116](/filings/0001193125-26-382016.md) |
| Cost of revenue | $m | [29.4](/filings/0001836833-23-000110.md) | [26.4 d](/filings/0001836833-24-000037.md) | [28.8](/filings/0001836833-24-000062.md) | [28.8](/filings/0001836833-25-000104.md) | [23.7](/filings/0001193125-25-314295.md) | [23.3 d](/filings/0001193125-26-119957.md) | [29.7](/filings/0001193125-26-258304.md) | [31.1](/filings/0001193125-26-382016.md) | [34.7](/filings/0001193125-25-314295.md) | [39.8 d](/filings/0001193125-26-119957.md) | [43.7](/filings/0001193125-26-258304.md) | [50.4](/filings/0001193125-26-382016.md) |
| Gross profit | $m | [26.0](/filings/0001836833-24-000118.md) | [32.5 d](/filings/0001193125-26-119957.md) | [31.7](/filings/0001836833-25-000063.md) | [32.3](/filings/0001836833-25-000104.md) | [37.5](/filings/0001193125-25-314295.md) | [38.2 d](/filings/0001193125-26-119957.md) | [36.6](/filings/0001193125-26-258304.md) | [42.3](/filings/0001193125-26-382016.md) | [46.6](/filings/0001193125-25-314295.md) | [47.0 d](/filings/0001193125-26-119957.md) | [50.4](/filings/0001193125-26-258304.md) | [65.6](/filings/0001193125-26-382016.md) |
| Research and development | $m | [33.0](/filings/0001836833-24-000118.md) | [28.4 d](/filings/0001193125-26-119957.md) | [25.6](/filings/0001836833-25-000063.md) | [27.3](/filings/0001836833-25-000104.md) | [25.2](/filings/0001193125-25-314295.md) | [23.0 d](/filings/0001193125-26-119957.md) | [23.1](/filings/0001193125-26-258304.md) | [24.2](/filings/0001193125-26-382016.md) | [27.3](/filings/0001193125-25-314295.md) | [32.2 d](/filings/0001193125-26-119957.md) | [33.4](/filings/0001193125-26-258304.md) | [35.2](/filings/0001193125-26-382016.md) |
| Operating income | $m | [(47.9)](/filings/0001836833-24-000118.md) | [(33.9) d](/filings/0001193125-26-119957.md) | [(34.6)](/filings/0001836833-25-000063.md) | [(39.6)](/filings/0001836833-25-000104.md) | [(22.6)](/filings/0001193125-25-314295.md) | [(19.4) d](/filings/0001193125-26-119957.md) | [(22.8)](/filings/0001193125-26-258304.md) | [(18.0)](/filings/0001193125-26-382016.md) | [(18.3)](/filings/0001193125-25-314295.md) | [(36.0) d](/filings/0001193125-26-119957.md) | [(34.9)](/filings/0001193125-26-258304.md) | [(13.5)](/filings/0001193125-26-382016.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | [0.3](/filings/0001193125-25-314295.md) | [0.3 d](/filings/0001193125-26-119957.md) | [0.5](/filings/0001193125-26-258304.md) | [0.3](/filings/0001193125-26-382016.md) | [1.0](/filings/0001193125-25-314295.md) | [1.6 d](/filings/0001193125-26-119957.md) | [1.4](/filings/0001193125-26-258304.md) | [1.4](/filings/0001193125-26-382016.md) |
| Income tax | $m | [0.4](/filings/0001836833-24-000118.md) | [(0.4) d](/filings/0001193125-26-119957.md) | [0.4](/filings/0001836833-25-000063.md) | [0.9](/filings/0001836833-25-000104.md) | [0.0](/filings/0001193125-25-314295.md) | [1.1 d](/filings/0001193125-26-119957.md) | [0.9](/filings/0001193125-26-258304.md) | [0.5](/filings/0001193125-26-382016.md) | [0.8](/filings/0001193125-25-314295.md) | [2.4 d](/filings/0001193125-26-119957.md) | [1.0](/filings/0001193125-26-258304.md) | [0.7](/filings/0001193125-26-382016.md) |
| Net income | $m | [(38.0)](/filings/0001836833-24-000118.md) | [(30.1) d](/filings/0001193125-26-119957.md) | [(29.3)](/filings/0001193125-25-314295.md) | [(38.7)](/filings/0001193125-25-314295.md) | [(20.1)](/filings/0001193125-25-314295.md) | [(35.2) d](/filings/0001193125-26-119957.md) | [(12.6)](/filings/0001193125-26-382016.md) | [(22.6)](/filings/0001193125-26-382016.md) | [(59.2)](/filings/0001193125-25-314295.md) | [(152) d](/filings/0001193125-26-119957.md) | [(139)](/filings/0001193125-26-382016.md) | [(9.4)](/filings/0001193125-26-382016.md) |
| Diluted EPS | $ per share | [(0.13)](/filings/0001836833-24-000118.md) | not reported | [(0.10)](/filings/0001836833-25-000063.md) | [(0.13)](/filings/0001836833-25-000104.md) | [(0.07)](/filings/0001193125-25-314295.md) | not reported | [(0.04)](/filings/0001193125-26-258304.md) | [(0.07)](/filings/0001193125-26-382016.md) | [(0.19)](/filings/0001193125-25-314295.md) | not reported | [(0.40)](/filings/0001193125-26-258304.md) | [(0.03)](/filings/0001193125-26-382016.md) |
| Basic EPS | $ per share | [(0.13)](/filings/0001836833-24-000118.md) | not reported | [(0.10)](/filings/0001836833-25-000063.md) | [(0.13)](/filings/0001836833-25-000104.md) | [(0.07)](/filings/0001193125-25-314295.md) | not reported | [(0.04)](/filings/0001193125-26-258304.md) | [(0.07)](/filings/0001193125-26-382016.md) | [(0.19)](/filings/0001193125-25-314295.md) | not reported | [(0.40)](/filings/0001193125-26-258304.md) | [(0.03)](/filings/0001193125-26-382016.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [102](/filings/0001836833-23-000110.md) | [83.9](/filings/0001836833-25-000050.md) | [107](/filings/0001836833-24-000062.md) | [148](/filings/0001836833-24-000102.md) | [139](/filings/0001836833-24-000118.md) | [118](/filings/0001193125-26-119957.md) | [133](/filings/0001836833-25-000063.md) | [181](/filings/0001836833-25-000104.md) | [443](/filings/0001193125-25-314295.md) | [229](/filings/0001193125-26-382016.md) | [368](/filings/0001193125-26-258304.md) | [415](/filings/0001193125-26-382016.md) |
| Current assets | $m | [388](/filings/0001836833-23-000110.md) | [370](/filings/0001836833-25-000050.md) | [346](/filings/0001836833-24-000062.md) | [327](/filings/0001836833-24-000102.md) | [302](/filings/0001836833-24-000118.md) | [302](/filings/0001193125-26-119957.md) | [325](/filings/0001836833-25-000063.md) | [355](/filings/0001836833-25-000104.md) | [754](/filings/0001193125-25-314295.md) | [775](/filings/0001193125-26-382016.md) | [849](/filings/0001193125-26-258304.md) | [999](/filings/0001193125-26-382016.md) |
| Total assets | $m | [714](/filings/0001836833-23-000110.md) | [702](/filings/0001836833-25-000050.md) | [675](/filings/0001836833-24-000062.md) | [658](/filings/0001836833-24-000102.md) | [631](/filings/0001836833-24-000118.md) | [634](/filings/0001193125-26-119957.md) | [658](/filings/0001836833-25-000063.md) | [696](/filings/0001836833-25-000104.md) | [1,106](/filings/0001193125-25-314295.md) | [1,146](/filings/0001193125-26-382016.md) | [1,251](/filings/0001193125-26-258304.md) | [1,431](/filings/0001193125-26-382016.md) |
| Current liabilities | $m | [131](/filings/0001836833-23-000110.md) | [137](/filings/0001836833-25-000050.md) | [126](/filings/0001836833-24-000062.md) | [140](/filings/0001836833-24-000102.md) | [129](/filings/0001836833-24-000118.md) | [142](/filings/0001193125-26-119957.md) | [155](/filings/0001836833-25-000063.md) | [203](/filings/0001836833-25-000104.md) | [189](/filings/0001193125-25-314295.md) | [469](/filings/0001193125-26-382016.md) | [303](/filings/0001193125-26-258304.md) | [351](/filings/0001193125-26-382016.md) |
| Total liabilities | $m | [180](/filings/0001836833-23-000110.md) | [184](/filings/0001836833-25-000050.md) | [174](/filings/0001836833-24-000062.md) | [185](/filings/0001836833-24-000102.md) | [166](/filings/0001836833-24-000118.md) | [193](/filings/0001193125-26-119957.md) | [214](/filings/0001836833-25-000063.md) | [261](/filings/0001836833-25-000104.md) | [757](/filings/0001193125-25-314295.md) | [957](/filings/0001193125-26-382016.md) | [808](/filings/0001193125-26-258304.md) | [867](/filings/0001193125-26-382016.md) |
| Shareholders' equity | $m | [534](/filings/0001836833-24-000118.md) | [518](/filings/0001193125-26-119957.md) | [500](/filings/0001193125-25-314295.md) | [473](/filings/0001193125-25-314295.md) | [465](/filings/0001193125-25-314295.md) | [441](/filings/0001193125-26-382016.md) | [445](/filings/0001193125-26-382016.md) | [436](/filings/0001193125-26-382016.md) | [350](/filings/0001193125-25-314295.md) | [188](/filings/0001193125-26-382016.md) | [444](/filings/0001193125-26-382016.md) | [564](/filings/0001193125-26-382016.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(22.9) d](/filings/0001836833-24-000118.md) | [(6.8) d](/filings/0001193125-26-119957.md) | [(4.3)](/filings/0001836833-25-000063.md) | [(7.9) d](/filings/0001836833-25-000104.md) | [4.1 d](/filings/0001193125-25-314295.md) | [(6.3) d](/filings/0001193125-26-119957.md) | [17.3](/filings/0001193125-26-258304.md) | [67.8 d](/filings/0001193125-26-382016.md) | [28.6 d](/filings/0001193125-25-314295.md) | [20.6 d](/filings/0001193125-26-119957.md) | [15.4](/filings/0001193125-26-258304.md) | [52.9 d](/filings/0001193125-26-382016.md) |
| Capital expenditure | $m | [7.4 d](/filings/0001836833-24-000118.md) | [8.9 d](/filings/0001193125-26-119957.md) | [9.9](/filings/0001836833-25-000063.md) | [15.1 d](/filings/0001836833-25-000104.md) | [7.6 d](/filings/0001193125-25-314295.md) | [11.6 d](/filings/0001193125-26-119957.md) | [8.1](/filings/0001193125-26-258304.md) | [20.3 d](/filings/0001193125-26-382016.md) | [26.7 d](/filings/0001193125-25-314295.md) | [21.6 d](/filings/0001193125-26-119957.md) | [17.3](/filings/0001193125-26-258304.md) | [27.3 d](/filings/0001193125-26-382016.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [268](/filings/0001836833-23-000110.md) | [272](/filings/0001836833-24-000062.md) | [275](/filings/0001836833-24-000102.md) | [284](/filings/0001836833-24-000118.md) | [288](/filings/0001836833-25-000063.md) | [290](/filings/0001836833-25-000104.md) | [293](/filings/0001193125-25-314295.md) | [300](/filings/0001193125-26-258304.md) | [304](/filings/0001193125-26-382016.md) | [309](/filings/0001193125-25-314295.md) | [346](/filings/0001193125-26-258304.md) | [360](/filings/0001193125-26-382016.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.